Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

CD59 Silencing via Retrovirus-Mediated RNA Interference Enhanced Complement-Mediated Cell Damage in Ovary Cancer

(2010) Xuexiang Shi et al.   Cellular & Molecular Immunology

In vivo Model of Follicular Lymphoma Resistant to Rituximab

(2009) S. Dalle et al.   CLINICAL CANCER RESEARCH

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

(2009) Jorge Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Intermedilysin-Receptor Interactions during Assembly of the Pore Complex

(2009) Stephanie LaChapelle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Update in the management of chronic lymphocytic leukemia

(2009) Kami J Maddocks et al.   Journal of Hematology & Oncology

A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS

(2009) Weiguo Hu et al.   JOURNAL OF IMMUNOLOGY

Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59

(2009) Timothy R. Hughes et al.   MOLECULAR IMMUNOLOGY

Development of IGF-IR inhibitors in pediatric sarcomas

(2009) E. Anders Kolb et al.   Current Oncology Reports

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Anti-CD20 monoclonal antibody therapy in multiple myeloma

(2008) Prashant Kapoor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma

(2008) R. M. Donev et al.   CANCER RESEARCH

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

(2008) X. Zhou et al.   ONCOLOGIST